Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Clinical Cancer Research|2022Cited by 26
Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.Jennifer L. Leddon, Trisha M. Wise‐Draper, Sulsal Haque et al.|Journal of Clinical Oncology|2021Cited by 5
Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).Eejung Kim, Trisha M. Wise‐Draper, Sarah Palackdharry et al.|Journal of Clinical Oncology|2018Cited by 4
Data from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Sarah Palackdharry et al.|Unknown|2023Cited by 1
Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck CancerSarah Palackdharry, Trisha M. Wise‐Draper, Maura L. Gillison et al.|International Journal of Radiation Oncology*Biology*Physics|2018Cited by 1